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Abstract
We report the emergence of carbapenem-resistant Enterobacteri-
aceae in Austria. Over a 10-year period, carbapenem-resistant
Enterobacteriaceae isolates were obtained from 13 hospitalized
patients, with the ﬁrst isolation in the year 2005 and a remark-
able increase in the number of involved patients in 2010. Carba-
penem-resistant Enterobacteriaceae comprise eight Klebsiella
pneumoniae isolates, four Klebsiella oxytoca isolates, and one
Escherichia coli isolate. The detected carbapenemases were the
metallo-b-lactamases New Delhi b-lactamase, VIM and IMP, and
the serin-b-lactamase Klebsiella pneumoniae carbapenemase.
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The emergence of carbapenem-resistant Enterobacteriaceae
has become a substantial global health problem. An increas-
ing number of reports demonstrate that the epidemiology of
carbapenem-resistant Gram-negative bacteria varies because
of the diversity of carbapenem-hydrolysing enzymes [1,2].
Carbapenem-hydrolysing b-lactamases have been described
in all four Ambler classes of b-lactamases but, epidemiologi-
cally, the majority of carbapenemases belong to three of them,
namely Ambler class A, with Klebsiella pneumoniae carbapene-
mases (KPCs), class B, with the metallo-b-lactamases (MBLs)
IMP, VIM, SPM, GIM, and SIM, and the recently described New
Delhi b-lactamase (NDM-1), and class D b-lactamases, with
the OXA-type carbapenemases [1,3].
K. pneumoniae with KPC was ﬁrst detected in 1996 in
North Carolina, and has now spread all over the USA [1,4].
Outside the USA, KPC K. pneumoniae has recently been
reported in several European countries, including Greece,
Poland, Germany, and France [5]. Klebsiella oxytoca with KPC
has been described rarely [6].
MBLs in Enterobacteriaceae, especially VIMs and IMPs, are
endemic in Greece and are being increasingly reported in
several countries worldwide, with an overall increasing trend
and some major nosocomial outbreaks [5].
Enterobacteriaceae producing NDM-1 metallo b-lactamases
were ﬁrst reported from Pakistan and India, but can now be
found worldwide [3,7,8].
In this study, we report, for the ﬁrst time, the epidemiol-
ogy of carbapenem-resistant Enterobacteriaceae and the
involved carbapenem-hydrolysing enzymes in Austria.
All Enterobacteriaceae isolates detected in a 10-year period
from 2001 to 2010 at the Institute of Hygiene, Medical Univer-
sity Graz were analysed. The included isolates originated from
approximately 850 000 patient samples from different hospi-
tals in the south-east of Austria. Enterobacteriaceae isolates
resistant to at least one of the carbapenems imipenem, me-
ropenem or ertapenem according to the relevant CLSI criteria
were included [9]. For analysis, the primary isolate per patient
was retested. Identiﬁcation and susceptibility proﬁles were
determined with the VITEK II instrument (BioMerieux Vitek,
Hazelwood, MO, USA) and the Etest method (AB BioMerieux,
Solna, Sweden), and interpreted according to the CLSI guide-
lines [9]. The modiﬁed Hodge test and the MBL Etest (AB
BioMerieux) were used to screen for MBL production [9].
Primers and PCR protocols for MBL/IMP, SPM and VIM
were used as described by Pitout et al. [10], with some mod-
iﬁcations to also enable the detection of newer MBL sub-
types: forward primer for MBL/VIM, 5¢-GTTTGGTCGCATA
TCGCAAC-3¢; and reverse primer for MBL/VIM, 5¢-
CCATTCAGCCAGATCGGCATC-3¢. For MBL/GIM, a newly
designed forward primer, 5¢-TATCCTGGGCGACTGAC
AGG-3¢, in combination with the reverse primer as
described by Castanheira et al. [11], was used. Control
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strains were Pseudomonas aeruginosa (TS 832035) (VIM), and
two clinical isolates of P. aeruginosa, harbouring IMP and GIM
(conﬁrmed by sequencing). For KPC, OXA-48 and NDM-1,
the primers and PCR protocols were used as recently
described [12–14].
To determine clonal relationships, repetitive sequence-
based PCR (Rep-PCR) on the DiversiLab Instrument (bio-
Me´rieux) was performed [15].
Carbapenem-resistant Enterobacteriaceae isolates have
been detected in 13 patients, including eight K. pneumoniae
isolates, four K. oxytoca isolates, and one Escherichia coli iso-
late. The ﬁrst carbapenem-resistant Enterobacteriaceae isolate
was found in 2005. Carbapenem-resistant Enterobacteriaceae
isolates were rarely detected in the years that followed (one
in 2007, and two in 2009). In 2010, however, a remarkable
increase was noted, with carbapenem-resistant isolates being
isolated from nine patients. Patient data, susceptibility pat-
terns and travel history are shown in Table 1.
All detected carbapenem-resistant Enterobacteriaceae iso-
lates were multiresistant, and exhibited susceptibility to only
tigecycline (13/13), colistin (10/13), amikacin (10/13), fosfo-
mycin (5/13), and gentamicin (3/13).
The Hodge test was positive in 12 of 13 isolates (the nega-
tive isolate was No. 4), and MBL screening was negative in ﬁve
isolates (isolate No. 4 and all K. oxytoca isolates). Twelve of
the tested carbapenem-resistant Enterobacteriaceae isolates
gave a positive result for one or two of the investigated b-lac-
tamases: one for IMP, four for VIM, and three for NDM-1.
KPCs were detected in seven patients, and occurred in 2010
only. In one carbapenem-resistant K. pneumoniae isolate, none
of the investigated carbapenemases was detected (Table 1).
OXA-48, MBL/GIM and MBL/SPM could not be detected
in any of the investigated carbapenem-resistant Enterobacteri-
aceae isolates.
Rep-PCR on the DiversiLab Instrument assigned all iso-
lates as unrelated, with the exception of the four carbape-
nem-resistant K. oxytoca isolates in 2010 (Fig. 1).
Travel history was positive in six of the 13 patients. Two of
the NDM-1-positive patients returned from Pakistan and India,
and one patient was transferred from Kosovo. Two patients
with MBL/VIM-positive isolates had a history of travelling to
Greece; in one of the isolates, KPC was also identiﬁed. The
patient with the carbapenem-resistant K. pneumoniae isolate
that was negative for investigated carbapenemases was from
Bosnia. All of these patients had been admitted to hospitals in
their respective countries prior to presenting at Austrian hos-
pitals.
The worldwide spread of carbapenem-resistant Enterobac-
teriaceae is a challenge for clinicians and microbiologists. We
report the emergence of carbapenem-resistant Enterobacteria-
ceae in Austria and a remarkable increase in the number of
cases detected in 2010.
K. pneumoniae isolates with VIM-MBLs and KPC have been
found as causes of countrywide epidemics in the USA, sev-
eral Latin American countries, and China [4]. These enzymes
are also the most frequently isolated carbapenamases in Eur-
ope [5]. The spread of VIM-producing Enterobacteriaceae in
hospitals has emerged as a public health problem [16]. In this
study, VIM-positive K. pneumoniae isolates were obtained
from four patients. Two of them were hospitalized in Greece
prior to isolation of the pathogen. One of the detected carb-
apenem-resistant K. pneumoniae isolates gave negative results
for all investigated carbapenemases. The explanation for this
might be the use of carbapenems for therapy and the devel-
opment of mutants with lack of porin expression and
reduced permeability to carbapenems or the presence of a
carbapenemase not tested in this study [17]. The involved
patient originated from Bosnia, had been on dialysis, and had
TABLE 1. Clinical data, strains and detected carbapenemases in carbapenem-resistant Enterobacteriaceae in Austria, 2001–
2010
Organism
Year
detected
Patient’s
age (years)/sex
Location
of ﬁrst
detection Antibiotic susceptibility Infection/colonization
Travel
history
Carbapemases
detected
Klebsiella pneumoniae 2005 46/M Wound TGC Colonized No IMP
K. pneumoniae 2007 82/F Urine TGC, CST, AMK, GEN Colonized Greece VIM
K. pneumoniae 2009 30/M Wound TGC, CST, AMK Infected (sacral decubitus ulcer) Pakistan NDM-1
K. pneumoniae 2009 31/M Stool TGC, CST, AMK Colonized Bosnia None
K. pneumoniae 2010 43/M Wound TGC, CST, GEN Colonized No VIM, KPC
K. pneumoniae 2010 45/M Tracheal ﬂuid TGC, GM, AMK Bacteraemia/septicaemia Greece VIM, KPC
Escherichia coli 2010 56/M Wound TGC, CST, FOF Infected (necrotizing fasciitis) India NDM-1
K. pneumoniae 2010 14/M Wound TGC, CST, AMK Infected (abdominal wound) Kosovo NDM-1
K. pneumoniae 2010 75/M Tracheal ﬂuid TGC, AMK, GEN Colonized No VIM, KPC
Klebsiella oxytoca 2010 76/F Throat TGC, FOF, CST, AMK Infected, VAP, UTI No KPC
K. oxytoca 2010 43/F Urine TGC, FOF, CST, AMK Colonized No KPC
K. oxytoca 2010 43/M BAL TGC, FOF, CST, AMK Infected, VAP No KPC
K. oxytoca 2010 70/M Wound TGC, FOF, CST, AMK Colonized No KPC
AMK, amikacin; BAL, bronchoalveolar lavage ﬂuid; CST, colistin; F, female; FOF, fosfomycin; GEN, gentamicin; M, male; KPC, Klebsiella pneumoniae carbapenemase; NDM-1,
New Delhi b-lactamase; TGC, tigecycline; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.
E6 Clinical Microbiology and Infection, Volume 17 Number 11, November 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, E5–E8
therefore been frequently admitted to hospitals in Bosnia
and Austria.
Healthcare-associated infections with carbapenem-resis-
tant Enterobacteriaceae, mainly KPC-positive K. pneumoniae,
have been reported in Greece, the USA, some Latin Ameri-
can countries, and Italy. These reports demonstrate an
increased risk of complications and death when patients are
infected with carbapenem-resistant Enterobacteriaceae [18]. In
this study, the ﬁrst KPC-positive K. pneumoniae isolates were
detected in 2010, and KPCs were found not only in K. pneu-
moniae, but also in K. oxytoca. Upon admission to hospitals,
screening for multidrug-resistant organisms should be per-
formed in patients who have received healthcare in endemic
countries or endemic facilities [19,20].
To summarize, in Austria carbapenem-resistant Enterobac-
teriaceae isolates were detected in the relatively low number
of 13 patients after 2001. The detected b-lactamases
included VIM, IPM, and NDM-1. KPCs in Enterobacteriaceae
were detected in seven patients in 2010.
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